Skip to main navigation
Skip to main content
Skip to Footer
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity & Inclusion
Our Leadership
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
External Funding
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
The STEP Program
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Career Paths
Career Programs
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2022
April
Media Release
/
Apr 12, 2022
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Read More
Media Release
/
Apr 06, 2022
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Read More
March
Media Release
/
Mar 23, 2022
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
Read More
2021
December
Media Release
/
Dec 22, 2021
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Read More
Media Release
/
Dec 22, 2021
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
Read More
Media Release
/
Dec 13, 2021
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
Read More
Media Release
/
Dec 11, 2021
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Read More
Media Release
/
Dec 10, 2021
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
Read More
Media Release
/
Dec 08, 2021
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
Read More
November
Media Release
/
Nov 08, 2021
Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021
Read More
Share
Twitter
Facebook
LinkedIn
Email
Whatsapp
Jump to Comments
Print
Save
Related Links
News
You are here
Home
›
News